Is NovaBridge Biosciences (NBP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 43.0% / 30% | 0.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 43.0% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.8% / 33% | 81.5% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 43.0% / 33% | 0.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.8% / 33% | 81.5% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$53M |
| Free Cash Flow | -$53M |
| Total Debt | $4M |
| Debt-to-Equity | 1.3 |
| Current Ratio | 14.5 |
| Total Assets | $213M |
Price & Trading
| Last Close | $2.55 |
| 50-Day MA | $3.29 |
| 200-Day MA | $3.66 |
| Avg Volume | 775K |
| Beta | 1.7 |
|
52-Week Range
$0.59
| |
About NovaBridge Biosciences (NBP)
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NovaBridge Biosciences (NBP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NovaBridge Biosciences is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NovaBridge Biosciences's debt ratio?
NovaBridge Biosciences's debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.8%.
What are NovaBridge Biosciences's key financial metrics?
NovaBridge Biosciences has a market capitalization of $293M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.